TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T37539	B-cell receptor CD22	B2QH9N	(2R,4S,5R,6R)-6-[(1R,2R)-3-[[4-(4-Carboxyphenyl)benzoyl]amino]-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	Investigative	25140893	C38H44N2O18	816.8	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CNC(=O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(=O)O)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 73250 nM	Poor binder
T37539	B-cell receptor CD22	B36LGH	(2R,4S,5R,6R)-6-[(1R,2R)-3-[(5-Chloro-2-hydroxybenzoyl)amino]-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	Investigative	25140161	C31H39ClN2O17	747.1	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CNC(=O)C4=C(C=CC(=C4)Cl)O)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 115850 nM	Poor binder
T37539	B-cell receptor CD22	B7I9EK	(2R,4S,5R,6R)-6-[(1R,2R)-3-Amino-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	Investigative	25140006	C24H36N2O15	592.5	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CN)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 85000 nM	Poor binder
T37539	B-cell receptor CD22	BG5FC4	(2R,4S,5R,6R)-6-[(1R,2R)-3-(Benzylamino)-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	Investigative	25140894	C31H42N2O15	682.7	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CNCC4=CC=CC=C4)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 122570 nM	Poor binder
T37539	B-cell receptor CD22	BO4HQ6	(2R,4S,5R,6R)-6-[(1R,2R)-1,2-Dihydroxy-3-[(2-hydroxybenzoyl)amino]propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	Investigative	25140160	C31H40N2O17	712.7	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CNC(=O)C4=CC=CC=C4O)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 192670 nM	Poor binder
T37539	B-cell receptor CD22	BOQ2H8	(2R,4S,5R,6R)-6-[(1R,2R)-1,2-Dihydroxy-3-(pyridine-3-carbonylamino)propyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	Investigative	25140162	C30H39N3O16	697.6	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CNC(=O)C4=CN=CC=C4)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 132320 nM	Poor binder
T37539	B-cell receptor CD22	BXRC43	(2R,4S,5R,6R)-6-[(1R,2R)-3-Benzamido-1,2-dihydroxypropyl]-4-hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]oxane-2-carboxylic acid	Investigative	25140159	C31H40N2O16	696.7	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CNC(=O)C4=CC=CC=C4)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 125160 nM	Poor binder
T37539	B-cell receptor CD22	BXZT57	(2R,4S,5R,6R)-4-Hydroxy-5-[(2-hydroxyacetyl)amino]-2-[[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methoxyphenoxy)oxan-2-yl]methoxy]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid	Investigative	25140005	C24H35NO16	593.5	COC1=CC=C(C=C1)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO[C@@]3(C[C@@H]([C@H]([C@@H](O3)[C@@H]([C@@H](CO)O)O)NC(=O)CO)O)C(=O)O)O)O)O	IC50 = 148330 nM	Poor binder